ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In another phase I/II study (NCT03348033) assessing the safety and feasibility of autologous activated and expanded NK cells in CML, infusion of NK cells significantly reduced BCR-ABL gene expression compared to untreated controls (Table 1).